Chanson Chang

Chanson Chang — Patent Litigation Practice Summary

Focus areas. Chang's tracked and verifiable patent work is concentrated in life sciences — biologics/biosimilars and pharmaceutical formulations rather than electronics, software, or mechanical arts. His tracked appearance is in Regeneron Pharmaceuticals, Inc. v. Amgen Inc., part of the consolidated aflibercept (Eylea®/Pavblu®) BPCIA litigation over Regeneron's U.S. Patent No. 11,084,865, which concerns ophthalmic formulations of a VEGF-trap fusion protein. Court records also show him appearing for Amgen in OssiFi-Mab LLC v. Amgen Inc. (D. Mass., 1:23-cv-10861), an antibody-patent suit. Earlier in private practice he was on the Covington & Burling trial team representing Pharmacyclics LLC (an AbbVie affiliate) in the Imbruvica® (ibrutinib) patent litigation in D. Del., a small-molecule/pharmaceutical case.

Side preference. On the authoritative tracked data he is 0–1, entirely defendant-side and acting in-house. That reflects his current role: as Amgen in-house counsel he defends an operating company against brand-vs.-biosimilar and third-party plaintiff assertions. His prior private-practice work included patent-owner-side representation (Pharmacyclics/AbbVie asserting Imbruvica patents), so his experience is not exclusively defensive, but the verified docket record places him squarely on the operating-company defense side.

Firm context. He is currently Senior Counsel, Intellectual Property & Litigation at Amgen Inc. (Thousand Oaks, CA), and appears as Amgen's counsel of record on Federal Circuit briefing in the aflibercept appeals (alongside Eric Agovino, Pauline Pelletier, and Wendy A. Whiteford). Before moving in-house he practiced at Covington & Burling LLP in Washington, DC, where he was part of the firm's IP litigation group; a third-party Super Lawyers profile still lists Covington, suggesting a stale listing. Given multiple attorneys share variants of this name, I matched the DC/Covington IP-litigation profile to the Amgen in-house lawyer on the basis of the Imbruvica trial-team listing and bar/education data, but the link is not confirmed by a single primary source.

Notable matters and outcomes. The most prominent tracked matter is Regeneron v. Amgen: the district court denied Regeneron's preliminary injunction against Amgen's ABP 938 (Pavblu®) after construing the '865 claims to require the VEGF antagonist and buffer to be separate components — Amgen's product is self-buffering, so no separate buffer is present. The Federal Circuit affirmed on March 14, 2025, clearing the way for the biosimilar's launch. In the Imbruvica matter, the Covington team (including Chang) secured a ruling from Judge Colm Connolly that the asserted Pharmacyclics patents were valid and infringed by Alvogen, and the team was recognized as Law360 "Litigators of the Week" (2021). Related Regeneron affiliate actions were later dismissed by stipulation in the MDL.

PTAB / IPR. No PTAB or IPR appearances by him are confirmed in the sources reviewed. The '865 patent at issue in the Amgen litigation has drawn IPR petitions from Samsung Bioepis, Formycon, and Celltrion (late 2024–early 2025), but I found no record of Chang personally appearing in those proceedings; treat any IPR-experience claim as unverified.

Bar / education. Third-party profiles state a J.D. from Northwestern University School of Law (2011) and District of Columbia bar admission (2012); the DC admission date is consistent with later pro hac vice admissions, but I could not confirm this against a primary bar or firm source.